Despite COVID-hospitalised control patients exhibiting a more severe COVID-19 illness (Table 1), there were no significant differences in titres between aβ2GP1 IgA (p = 0.152) and IgG (p = 0.338), aCL IgM (p = 0.761) and aD1β2GPI IgG (p = 0.270) compared with the COVID-neurological group (Fig. 1). The gene discussed is ACLY; the disease is COVID-19.